Jupiter Neurosciences Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
No analyst estimates are published for this company.
Coverage varies across the market: larger companies are often followed by dozens of analysts, while smaller or recently listed ones may have none.
Monitoring Framework
Key Performance Indicators
RESET Phase IIa Trial Patient Enrollment QuarterlyTarget: Full enrollment of Parkinson's disease patients
Nugevia Product Line Net Revenue Quarterly21.8KTarget: Revenue growth and expansion of DTC sales
Cash and Cash Equivalents Balance Quarterly2.4MTarget: Maintain sufficient runway to fund Phase IIa clinical operations
Watch Items
- Nasdaq Minimum Bid Price Requirement ComplianceTrigger: Closing bid price below $1.00 per share for 30 consecutive business daysAction: Regain compliance by maintaining a closing bid price of at least $1.00 for a minimum of 10 consecutive business days before the August 25, 2026 deadline, or execute a reverse stock split.
- Nasdaq Market Value of Listed Securities (MVLS) ComplianceTrigger: MVLS below $35 millionAction: Regain compliance with the $35 million MVLS requirement by the August 25, 2026 deadline.
- Outstanding Convertible Promissory NotesTrigger: Outstanding principal balance of $5,527,625 as of March 31, 2026Action: Monitor debt service requirements, conversion activities, and potential equity dilution under the Standby Equity Purchase Agreement (SEPA) with Yorkville Advisors.
Research as of 20 Jun 2026